52 Week Range
As of on the XETRA ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Fresenius Medical Care Says FDA Approved Delflex Dialysis Solutions In Biofine Bags
Fresenius Medical Care Gets FDA Approval For Biofine PD Solution Bags
FMC Announces New Medium-Term Targets Until 2025
Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Chairman of the Supervisory Board
Chairman of the Management Board, Chief Executive Officer
Ben J. Lipps
Rolf A. Classon
Independent Vice Chairman of the Supervisory Board
Chief Financial Officer, Member of the Management Board
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
German dialysis specialist Fresenius Medical Care beat third-quarter net income expectations on Thursday, as it was able to maintain operations and minimize risk for its patients during the COVID-19 pandemic.
* Shares down 4% (Adds details from conference call, updates shares)
German dialysis specialist Fresenius Medical Care beat second-quarter net income expectations on Thursday, citing lower negative impact of the coronavirus pandemic compared to the previous quarter and strong underlying business performance.
* FRESENIUS MEDICAL CARE HOLDS VIRTUAL GENERAL MEETING ON AUGUST 27, 2020 - DIVIDEND PROPOSAL UNCHANGED
* EXPANDS PRODUCTION AT ST. WENDEL PLANT IN RESPONSE TO HIGHER DEMAND CAUSED BY COVID-19 PANDEMIC
German dialysis provider Fresenius Medical Care (FMC) <FMEG.DE> confirmed on Thursday that patient data from some of its dialysis centres in Serbia leaked after a recent hacker attack.
* SAYS PLACED BONDS WITH A TOTAL VOLUME OF 1.25 BILLION EUROS
Healthcare group Fresenius <FREG.DE> beat first-quarter net income expectations on Wednesday, citing a U.S. and European spike in demand for drugs and devices for COVID-19 patients and government help with costs incurred by health providers.
German dialysis specialist Fresenius Medical Care <FMEG.DE> beat first-quarter net income expectations on Wednesday, saying its strong underlying business offset costs related to the coronavirus pandemic.
* POSITIVE EARNINGS GROWTH DESPITE NEGATIVE IMPACT FROM COVID-19
(All figures in EUR) * Fresenius Medical Care AG & Co KGaA reports its first quarter results on May 6. * Year to date, Fresenius Medical Care AG & Co KGaA shares are up 8.64%. * Below is a table of analyst estimates for quarterly and annual results based on Refinitiv data...
* FRESENIUS KABI TAKES COMPREHENSIVE MEASURES TO INCREASE SUPPLY OF ESSENTIAL DRUGS DURING COVID-19 PANDEMIC
Fresenius Medical Care (FMC) on Wednesday said it was working with other dialysis providers to provide care in isolation for people with kidney problems in the United States who are or may be infected with coronavirus.
* POSTPONES ITS 2020 ANNUAL GENERAL MEETING, WHICH WAS SCHEDULED FOR MAY 19, TO A LATER DATE THIS YEAR DUE TO CORONAVIRUS PANDEMIC
* US FOOD AND DRUG ADMINISTRATION APPROVES FRESENIUS MEDICAL CARE FOR NOVALUNG FOR THE TREATMENT OF ACUTE LUNG AND CARDIOPULMONARY FAILURE
German healthcare group Fresenius <FREG.DE> said it expects net income to increase in 2020 after strong growth in its dialysis business, and in its infusion drugs unit in emerging markets, helped it to just beat fourth quarter expectations.
Fresenius Medical Care (FMC) , the world's largest kidney dialysis provider, is confident the U.S. government will soften initial targets for treating patients with kidney disease at home rather than in dedicated centres.
Germany's Fresenius Medical Care <FMEG.DE> on Wednesday said quarterly adjusted operating income edged 3% higher as growth in dialysis services and products was partly offset by a negative adjustment for accounts receivable in a legal dispute in North America.
Germany's Fresenius Medical Care on Wednesday said quarterly adjusted operating income edged 3% higher as growth in dialysis services and products was partly offset by a negative adjustment for accounts receivable in a legal dispute in North America.
* Fresenius highlights infusion drugs unit growth in emerging markets (Adds details from conference call and analyst comments, updates share price)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.